Astellas Pharma Inc
Company Profile
Business description
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
Contact
2-5-1 Nihonbashi-Honcho
Chuo-ku
Tokyo103-8411
JPNT: +81 332443000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 March 2026
Employees
13,643
Stocks News & Analysis
stocks
Undervalued Aussie e-commerce winner
stocks
Our view on oil prices after Maduro is deposed
stocks
Nvidia: Full steam ahead with an impressive array of announcements at CES 2026
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,018.00 | 21.50 | -0.24% |
| CAC 40 | 8,226.52 | 10.91 | -0.13% |
| DAX 40 | 25,038.20 | 146.00 | 0.59% |
| Dow JONES (US) | 49,462.08 | 484.90 | 0.99% |
| FTSE 100 | 10,055.02 | 67.71 | -0.67% |
| HKSE | 26,458.95 | 251.50 | -0.94% |
| NASDAQ | 23,547.17 | 151.35 | 0.65% |
| Nikkei 225 | 51,961.98 | 556.10 | -1.06% |
| NZX 50 Index | 13,715.02 | 51.44 | 0.38% |
| S&P 500 | 6,944.82 | 42.77 | 0.62% |
| S&P/ASX 200 | 8,695.60 | 27.90 | -0.32% |
| SSE Composite Index | 4,085.77 | 2.10 | 0.05% |